T-DM1, which is the first antibody-drug conjugate (ADC) approved for clinical use, is designed to decompose in lysosomes and disrupt microtubule organization, thereby selectively targeting HER2 + malignant tumor cells [20,22–24]. Here, ERBB2 is linked to neoplasm.